Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Primary Objective: To compare LixiLan to lixisenatide in glycated hemoglobin (HbA1c) change from baseline to Week 26 in patients with type 2 diabetes mellitus. Secondary Objective: To compare the overall efficacy and safety of LixiLan to lixisenatide (with or without OADs) over a 52 week treatment period in patients with type 2 diabetes mellitus.
Critère d'inclusion
- Type 2 diabetes mellitus